Inhibiting TRPV6 channels reduces the proliferative capacity of breast cancer cells and enhances their sensitivity to chemotherapeutic agents (Peters et al., 2012; Xu et al., 2021). This evidence concerns the gene TRPV6 and breast carcinoma.